Verrica Pharmaceuticals Inc VRCA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$3.83 up $0.25, 6.98% at close Oct 14
Last close · Previous close $3.58
- Market cap
- At the Oct 14 close
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- Last 12 months
Price chart
$3.83up $0.25, 6.98%Wed, Oct 14 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$3.58Oct 13
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Valuation
Financials
Dividends
About Verrica Pharmaceuticals Inc
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
VRCA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VRCA stock FAQ
What is VRCA stock’s price today?
Verrica Pharmaceuticals (VRCA) traded at $3.83 at the close on , up $0.25 (6.98%) from the previous close of $3.58.
What exchange does VRCA trade on?
Verrica Pharmaceuticals trades on the Nasdaq under the ticker symbol VRCA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.